肿瘤相关性贫血的研究进展

Research progress on cancer related anemia

肿瘤相关性贫血(cancer related anemia,CRA)是指肿瘤患者出现的贫血。其发生率与肿瘤类型、临床分期及治疗干预等因素有关。CRA由促红细胞生成素减少、铁调素上调的作用、骨髓造血功能减退以及肿瘤引起的溶血引起。CRA可使肿瘤患者的生活质量下降、使肿瘤患者预后不良。CRA的治疗包括病因治疗、促红细胞生成素治疗、铁剂治疗及输血治疗等,而基于CRA潜在治疗靶点组合的治疗策略是非常值得期待的。

Cancer related anemia(CRA) refers to anemia that occurs in cancer patients. Its incidence varies depending on factors such as tumor type, clinical stage, and treatment intervention. CRA is caused by reduced erythropoietin, upregulation of ferritin, decreased bone marrow hematopoiesis, and tumor induced hemolysis. CRA can lead to a decline in the quality of life and poor prognosis for cancer patients. The treatment of CRA includes etiological therapy, erythropoietin therapy, iron supplementation therapy, and blood transfusion therapy, and the treatment strategy based on the potential therapeutic target combination of CRA is highly anticipated.